» Articles » PMID: 37759480

Silk Peptide Ameliorates Sarcopenia Through the Regulation of Akt/mTOR/FoxO3a Signaling Pathways and the Inhibition of Low-Grade Chronic Inflammation in Aged Mice

Overview
Journal Cells
Publisher MDPI
Date 2023 Sep 28
PMID 37759480
Authors
Affiliations
Soon will be listed here.
Abstract

As populations around the world age, interest in healthy aging is growing. One of the first physical changes that occurs with aging is the loss of muscle mass and strength, termed sarcopenia. Sarcopenia limits the activity of older people, reduces their quality of life, and increases the likelihood of their developing disease. In the present study, we aimed to evaluate the effects of the ingestion of acid-hydrolyzed silk peptide (SP) on the muscle mass and strength of mice of >22 months of age with naturally occurring sarcopenia, and to identify the mechanisms involved. The daily administration of SP for 8 weeks increased the activation of the Akt/mTOR/FoxO3a signaling pathways and increased the muscle mass and strength of the old mice. In addition, SP inhibited oxidative stress and inflammation in muscle, which are direct causes of sarcopenia. Therefore, SP represents a promising potential treatment for sarcopenia that may improve the healthy lifespan and quality of life of older people.

Citing Articles

Epigenetic factors and inflammaging: FOXO3A as a potential biomarker of sarcopenia and upregulation of DNMT3A and SIRT3 in older adults.

Bogucka D, Wajda A, Stypinska B, Radkowski M, Targowski T, Modzelewska E Front Immunol. 2025; 16:1467308.

PMID: 40034697 PMC: 11872893. DOI: 10.3389/fimmu.2025.1467308.


Comment on 'Artificial Neural Network Inference Analysis Identified Novel Genes and Gene Interactions Associated With Skeletal Muscle Aging' by Tarum et al.

Zheng J, Chen X, Li Y, Liu H J Cachexia Sarcopenia Muscle. 2024; 16(1):e13680.

PMID: 39723574 PMC: 11669945. DOI: 10.1002/jcsm.13680.


The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance.

Liu Z, Lei T, Guo Y, Zheng C Front Pharmacol. 2024; 15:1377666.

PMID: 39101140 PMC: 11294093. DOI: 10.3389/fphar.2024.1377666.


Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy.

Liu Z, Guo Y, Zheng C Front Endocrinol (Lausanne). 2024; 15:1375610.

PMID: 38854688 PMC: 11157032. DOI: 10.3389/fendo.2024.1375610.

References
1.
Ji Y, Li M, Chang M, Liu R, Qiu J, Wang K . Inflammation: Roles in Skeletal Muscle Atrophy. Antioxidants (Basel). 2022; 11(9). PMC: 9495679. DOI: 10.3390/antiox11091686. View

2.
Fry C, Rasmussen B . Skeletal muscle protein balance and metabolism in the elderly. Curr Aging Sci. 2011; 4(3):260-8. PMC: 5096733. DOI: 10.2174/1874609811104030260. View

3.
Gumucio J, Mendias C . Atrogin-1, MuRF-1, and sarcopenia. Endocrine. 2012; 43(1):12-21. PMC: 3586538. DOI: 10.1007/s12020-012-9751-7. View

4.
Rom O, Reznick A . The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med. 2016; 98:218-230. DOI: 10.1016/j.freeradbiomed.2015.12.031. View

5.
Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P . FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007; 6(6):458-71. DOI: 10.1016/j.cmet.2007.11.001. View